The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT00700817. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes inadequately controlled with metformin alone. The trial has been extended by 52 weeks. The extension will consist of two 26-week periods: 1. Week 27-52 after randomisation \- All subjects will continue receiving sitagliptin or liraglutide at unchanged dose and dosing regimen. 2. Week 53-78 after randomisation * Subjects receiving sitagliptin at the end of week 52 after randomisation will discontinue sitagliptin and will be randomised 1:1 to liraglutide 1.2 mg/day or liraglutide 1.8 mg/day. Liraglutide will be initiated at a dose of 0.6 mg/day, and increased to 1.2 mg/day or 1.8 mg/day in weekly intervals. * Subjects receiving liraglutide 1.2 mg/day or 1.8 mg/day at the end of week 52 after randomisation will continue the treatment at unchanged dose and dosing regimen. Trial completion is planned for June 2010.
Study identification
- NCT ID
- NCT00700817
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 665 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2008 (Type not available)
- Primary completion
- Jun 2009 (Actual)
- Completion
- Jun 2010 (Actual)
- Last update posted
- Mar 8, 2017
2008 – 2010
United States locations
- U.S. sites
- 60
- U.S. states
- 27
- U.S. cities
- 57
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Birmingham | Alabama | 35242 | — |
| Novo Nordisk Investigational Site | Escondido | California | 92025 | — |
| Novo Nordisk Investigational Site | Fresno | California | 93720 | — |
| Novo Nordisk Investigational Site | Huntington Beach | California | 92646 | — |
| Novo Nordisk Investigational Site | Long Beach | California | 90822 | — |
| Novo Nordisk Investigational Site | Northridge | California | 91325 | — |
| Novo Nordisk Investigational Site | Orange | California | 92869 | — |
| Novo Nordisk Investigational Site | Poway | California | 92064 | — |
| Novo Nordisk Investigational Site | Walnut Creek | California | 94598 | — |
| Novo Nordisk Investigational Site | Denver | Colorado | 80209 | — |
| Novo Nordisk Investigational Site | Crystal River | Florida | 34429 | — |
| Novo Nordisk Investigational Site | Jacksonville | Florida | 32205 | — |
| Novo Nordisk Investigational Site | Jacksonville | Florida | 32216 | — |
| Novo Nordisk Investigational Site | Miami | Florida | 33169 | — |
| Novo Nordisk Investigational Site | Ocala | Florida | 34471 | — |
| Novo Nordisk Investigational Site | Panama City | Florida | 32401 | — |
| Novo Nordisk Investigational Site | Saint Cloud | Florida | 34769 | — |
| Novo Nordisk Investigational Site | Athens | Georgia | 30606 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30342 | — |
| Novo Nordisk Investigational Site | Dunwoody | Georgia | 30338 | — |
| Novo Nordisk Investigational Site | Lithia Springs | Georgia | 30122 | — |
| Novo Nordisk Investigational Site | Honolulu | Hawaii | 96814 | — |
| Novo Nordisk Investigational Site | Boise | Idaho | 83702 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60616 | — |
| Novo Nordisk Investigational Site | Shawnee Mission | Kansas | 66204 | — |
| Novo Nordisk Investigational Site | Metairie | Louisiana | 70002 | — |
| Novo Nordisk Investigational Site | Hyattsville | Maryland | 20782 | — |
| Novo Nordisk Investigational Site | Minneapolis | Minnesota | 55416 | — |
| Novo Nordisk Investigational Site | Cleveland | Mississippi | 38732 | — |
| Novo Nordisk Investigational Site | City of Saint Peters | Missouri | 63376 | — |
| Novo Nordisk Investigational Site | Las Vegas | Nevada | 89109 | — |
| Novo Nordisk Investigational Site | Berlin | New Jersey | 08009 | — |
| Novo Nordisk Investigational Site | Northport | New York | 11768 | — |
| Novo Nordisk Investigational Site | Rosedale | New York | 11422 | — |
| Novo Nordisk Investigational Site | Pinehurst | North Carolina | 28374 | — |
| Novo Nordisk Investigational Site | Tabor City | North Carolina | 28463 | — |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45245 | — |
| Novo Nordisk Investigational Site | Columbus | Ohio | 43201 | — |
| Novo Nordisk Investigational Site | Cuyahoga Falls | Ohio | 44223 | — |
| Novo Nordisk Investigational Site | Dayton | Ohio | 45406 | — |
| Novo Nordisk Investigational Site | Dayton | Ohio | 45439 | — |
| Novo Nordisk Investigational Site | Mentor | Ohio | 44060 | — |
| Novo Nordisk Investigational Site | Eugene | Oregon | 97404 | — |
| Novo Nordisk Investigational Site | Altoona | Pennsylvania | 16602 | — |
| Novo Nordisk Investigational Site | Norristown | Pennsylvania | 19401 | — |
| Novo Nordisk Investigational Site | Kingsport | Tennessee | 37660 | — |
| Novo Nordisk Investigational Site | Arlington | Texas | 76014 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77024 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
| Novo Nordisk Investigational Site | Hurst | Texas | 76054 | — |
| Novo Nordisk Investigational Site | New Braunfels | Texas | 78130 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78229 | — |
| Novo Nordisk Investigational Site | Sugar Land | Texas | 77479 | — |
| Novo Nordisk Investigational Site | Ogden | Utah | 84403 | — |
| Novo Nordisk Investigational Site | St. George | Utah | 84790 | — |
| Novo Nordisk Investigational Site | South Burlington | Vermont | 05403 | — |
| Novo Nordisk Investigational Site | Newport News | Virginia | 23606 | — |
| Novo Nordisk Investigational Site | Richmond | Virginia | 23294 | — |
| Novo Nordisk Investigational Site | Milwaukee | Wisconsin | 53209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00700817, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2017 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00700817 live on ClinicalTrials.gov.